Navigation Links
Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
Date:1/17/2008

Study in Overweight and Obese Type 2 Diabetics to Assess Safety and

Pharmacokinetics in addition to Specialized Secondary Endpoints

PLYMOUTH MEETING, Pa., Jan. 17 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that dosing of subjects has begun in study MSI-1436C-103, the ascending single dose Phase 1 study of trodusquemine (MSI-1436), in overweight and obese type 2 diabetics. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which works centrally and peripherally to regulate insulin and leptin receptor signaling through inhibition of its novel target enzyme PTP-1B.

Study 103 is similar in design to the previously completed Study 101 which was conducted in healthy obese and overweight volunteers. The current study will continue to expand the safety database for MSI-1436 and establish the pharmacokinetics of the drug in a population of type 2 diabetics who are poorly controlled on metformin. The study will also evaluate a range of secondary endpoints including short-term insulin/glucose control indices, glucose tolerance and evaluation of insulin sensitivity.

"We have achieved another important milestone in the development of MSI- 1436 and can now begin collecting data from obese type 2 diabetics," said Jack Armstrong, President and Chief Executive Officer of Genaera. "The unique mechanism of action provides MSI-1436 with the potential to impact two of the key pathologies of type 2 diabetes: insulin resistance and obesity. We anticipate that this clinical study will provide a first step in demonstrating the safety of MSI-1436 in obese and overweight type 2 diabetics and will help determine an optimal therapeutic dose for this population."

This r
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Enrollment Begins on Human PK Study for Medidur(TM) FA
9. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
10. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
11. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  In part four of a ... pharmacy as a strategic asset, Mary Baxter, MBA, ... Cardinal Health,s Innovation Delivery Solutions business, discusses how expanding ... hospitals and patients. "Every hospital pharmacist knows ... their job in a value-based healthcare world," Baxter says. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Orthopedic Soft Tissue Repair Devices Market 2014-2018" ... tissues are the mass of cells that connect, support, ... soft tissues such as tendons, ligaments, cartilage, fascia, and ... degeneration of these tissues with age result in wear ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Services Industry (U.S.): Analytics, Extensive Financial ... 2021, NAIC 541380 ... Testing Laboratories, Safety and Compliance Services ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6
... /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX ) ... developing, manufacturing and marketing biopharmaceutical products, today announced that ... Tan, chief financial officer, will present at the Oppenheimer ... March 14-15, 2012 in New York City. ...
... 6, 2012  In a joint announcement today, the University of ... ERT ), report the launch of the ... patients suffering from Chronic Obstructive Pulmonary Disease (COPD).  COPD ... to the World Health Organization, will become the world,s ...
Cached Medicine Technology:ERT and UCLA Initiate Innovative Pilot Program for Chronically Ill Patients 2ERT and UCLA Initiate Innovative Pilot Program for Chronically Ill Patients 3ERT and UCLA Initiate Innovative Pilot Program for Chronically Ill Patients 4
(Date:8/29/2014)... 29, 2014 TayganPoint Consulting Group, a ... the second time, Inc. Magazine has named the company ... , Based on solid revenue growth of over 166% ... overall on the list. TayganPoint’s repeat success in ... the past few years, is a demonstration of its ...
(Date:8/29/2014)... Innovations Television, produced by DMG Productions, announced ... Innovations, focusing on health and elderly care, slated to air ... of Americans over 65 will nearly double by 2030, expanding ... 2030, for a total of 72 million people. Though many ... at least one chronic condition and use healthcare services more ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Fat is ... and bad fat. Brown fat is usually stored in the ... white fat typically reveals itself in overflowing bellies, muffin tops, ... fats occur naturally in many foods and promote better health, ... risks, including elevated bad cholesterol levels and lower good cholesterol ...
(Date:8/29/2014)... Scientists from four European countries say ... correlates with overall survival of mesothelioma. Surviving Mesothelioma has ... Click here to read it now. , Doctors ... cases of 523 mesothelioma patients who were ... [progression-free survival at 18 weeks after treatment] was strongly ...
(Date:8/29/2014)... Botanica Day Spa recently announced the ... menu along with a special introductory offer for the ... uses small glass cups to create a suctioning of ... a comfortable but effective pressure. The cups are then ... engage more tissue. In contrast, traditional massage primarily uses ...
Breaking Medicine News(10 mins):Health News:Innovations with Ed Begley, Jr., Seeking Content for Upcoming Series on Health and Elder Care 2Health News:Diet Doc Announces Modernized, Interesting and Easy to Follow Diet Plans that Deliver Fast Weight Loss and Teach Patients the Difference Between Good and Bad Fat 2Health News:Diet Doc Announces Modernized, Interesting and Easy to Follow Diet Plans that Deliver Fast Weight Loss and Teach Patients the Difference Between Good and Bad Fat 3Health News:European Study Says Disease Progression Predicts Mesothelioma Survival Better Than Treatment Response, According to Surviving Mesothelioma 2Health News:Cupping Massage Now Available at Botanica Day Spa in Clearwater, FL 2Health News:Cupping Massage Now Available at Botanica Day Spa in Clearwater, FL 3Health News:Cupping Massage Now Available at Botanica Day Spa in Clearwater, FL 4
... of adverse events for diabetes drug , , THURSDAY, Oct. ... should be banned in the United States because it ... other life-threatening risks that greatly outweigh its benefits, the ... said it has identified 14 cases of Avandia-induced liver ...
... epidemic is fueling the type 2 disease epidemic, officials say ... new cases of type 2 diabetes has nearly doubled in ... cases appearing in southern states, federal officials reported Thursday. , ... 1,000 people from 1995 to 1997 to 9.1 per 1,000 ...
... Pet Owners and Contribute to Research, BREA, ... sentence,for pets, cancer is claiming fewer four-legged victims ... of pet owners to pursue those,treatments. Veterinary Pet ... insurer, will seek to raise national awareness about ...
... Connextions Offers Best Practices and Lessons Learned from Other Industries, ... ... (PRWEB) October 30, 2008 -- Companies who have watched their ... or "Chat," are increasingly considering this technology for their own ...
... (Oct. 30, 2008) -- Weill Cornell Medical College announced ... Explorations grants from the Bill & Melinda Gates Foundation. ... "Untimely Triggering of the Fusion Mechanism Used by Viruses ... conducted by Dr. Anne Moscona, and "Senescent and Rejuvenated ...
... Interview Her Virtually at http://www.bodybymilk.com , WASHINGTON, ... graduating from high school, becoming a Billboard,chart-topping country super ... the Year, Swift has a hectic schedule. She knows ... she needs to stay in top shape. That,s,why she ...
Cached Medicine News:Health News:Consumer Group Seeks FDA Ban on Avandia 2Health News:Consumer Group Seeks FDA Ban on Avandia 3Health News:Rate of Diabetes Cases Doubles in 10 Years: CDC 2Health News:Rate of Diabetes Cases Doubles in 10 Years: CDC 3Health News:Veterinary Pet Insurance Kicks Off Fourth Annual Pet Cancer Awareness Month 2Health News:Veterinary Pet Insurance Kicks Off Fourth Annual Pet Cancer Awareness Month 3Health News:Companies Turn to Click-to-Chat Technology to Reduce Operating Expense and Enhance Customer Service 2Health News:Companies Turn to Click-to-Chat Technology to Reduce Operating Expense and Enhance Customer Service 3Health News:Companies Turn to Click-to-Chat Technology to Reduce Operating Expense and Enhance Customer Service 4Health News:Weill Cornell Medical College receives 2 $100,000 grants for innovative global health research 2Health News:Country Super Star Taylor Swift Stays Fearless With a Little Help From Milk 2
... Euclid Systems Orthokeratology (oprifocon A) Contact ... lenses used for orthokeratology, a process ... patient wears these lenses overnight and ... the day, nearsightedness is temporarily corrected ...
... rigid gas permeable contact lenses used for ... corrects nearsightedness (myopia). The patient wears the ... upon wakening. During the day, nearsightedness is ... and Quadra RG contact lenses apply slight ...
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... same as the model SP-8800 with one big exception. ... This mode has its own fixation targets to allow ... allows you to select an area on the cornea ... to calculate averages of multiple readings in any one ...
Medicine Products: